Navigation Links
PAREXEL And Korea Drug Development Fund Announce Alliance To Accelerate Global Drug Development And Commercialization
Date:7/19/2012

BOSTON, July 19, 2012 /PRNewswire/ -- PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced it is the first contract research organization (CRO) chosen by the Korea Drug Development Fund (KDDF) to help Korean companies develop and commercialize healthcare products for the global market.  

"Under the leadership of Dr. Dongho Lee, the KDDF is expected to be an important resource for emerging biopharmaceutical companies to advance their promising new technologies," said Ron Kraus, Corporate Vice President and Worldwide Head of PAREXEL Consulting and Medical Communications Services. "This partnership further demonstrates PAREXEL's continued commitment to the Asia-Pacific region and helps increase our opportunities for industry innovation. We are excited to provide our fusion of expertise to support KDDF and its mission of supporting global drug development."

"The Korea Drug Development Fund is pleased to work with PAREXEL to establish various collaborative channels providing essential resources to Korean academic and research institutions and biopharmaceutical companies," said Dr. Dong Ho Lee, CEO of KDDF. "Together with PAREXEL, KDDF will be able to provide professional consulting services to the Korean research communities to advance research activities and promote important innovation."

The KDDF is a consortium of three health-related Korean ministries: the Ministry of Knowledge Economy, the Ministry of Education, Science and Technology, and the Ministry of Health and Welfare. KDDF was established in September 2011 with assets of $1 billion to develop at least 10 new drugs by 2019 for the global market. Its alliance with PAREXEL enhances its development network and will provide access to a broad range of drug development support services for its selected investments. These services are tailored to meet the needs of Korean national companies and will span the entire drug development continuum. 

The alliance with KDDF follows PAREXEL's 2012 collaborative research agreement with ASAN Medical Center (AMC), based in Seoul, Korea. PAREXEL is one of Asia's leading providers of biopharmaceutical services and has had a presence in the Asia/Pacific region for over 16 years. PAREXEL has more than 2,800 employees and 21 offices throughout important industry centers in the region, including locations in Australia, China, Hong Kong, India, Indonesia, Japan, Malaysia, the Philippines, Singapore, South Korea, Taiwan, and Thailand. PAREXEL experts support biopharmaceutical companies in accessing diverse patient populations, navigating regulatory issues, identifying investigators, and ensuring data quality throughout the Asia/Pacific region.

About PAREXEL International PAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, consulting, and medical communications services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement.  Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process.  Headquartered near Boston, Massachusetts, PAREXEL operates in 71 locations throughout 50 countries around the world, and has approximately 11,920 employees. For more information about PAREXEL International visit www.PAREXEL.com.

This release contains "forward-looking" statements regarding future results and events, including, without limitation, statements regarding expected financial results, future growth and customer demand.
For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements.  Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," "estimates," "projects," "will," "would," "could," "should,"  "targets," and similar expressions are also intended to identify forward-looking statements.  The forward-looking statements in this release involve a number of risks and uncertainties.  The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release.  Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent and anticipated restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company's business of government regulation of the drug,  medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks.
Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2012 as filed with the SEC on May 10, 2012, which "Risk Factors" discussion is incorporated by reference in this press release.  The Company specifically disclaims any obligation to update these forward-looking statements in the future.  These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.

PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.Contacts:Georgina Cattaway, Director of Marketing

Kim Leadley/Sarah Bruckner PAREXEL International

PAN CommunicationsTel: +44 1895 614530

Tel: + 617-502-4300Email: Georgina.Cattaway@PAREXEL.com

Email: PAREXEL@pancomm.com 


'/>"/>
SOURCE PAREXEL International Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. PAREXEL Announces Date of Fourth Quarter and Fiscal Year 2012 Earnings Release and Conference Call
2. PAREXEL International To Present At NASDAQ OMX Investor Conference
3. PAREXEL International Issues Earnings Guidance In Conjunction With Investor Day
4. PAREXEL Chairman And CEO To Ring The Bell At The NASDAQ Stock Market Opening
5. Parexel Invites Public To Listen To Live Webcast Of Its Investor Day May 31, 2012
6. PAREXEL Reports Third Quarter Fiscal Year 2012 Financial Results
7. PAREXEL Chief Operating Officer Dr. Mark A. Goldberg Receives Special Recognition Award
8. Misonix And Soelim Create New Distribution Alliance For South Korea
9. Marken Opens Branch Office In Seoul, South Korea
10. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
11. HIV Immunity Study Could Pave Way for Vaccine Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... Texas , April 20, 2017  Vivify Health, ... mobile devices, has been awarded a very significant patent ... via EMRs to continual care via digital health.  This ... key intellectual property and further secures Vivify,s position as ... launched in 2009, was the first company to apply ...
(Date:4/20/2017)... DUBLIN , April 20, 2017 ... the "Global Biosimilar Pipeline and Market Prospects: Addressing ... report to their offering. ... "Global Biosimilar Pipeline and Market ... by Design" provides an in-depth assessment of the current ...
(Date:4/20/2017)... 2017 Research and Markets has announced the ... by Rapidly Expanding Injectables Market and Increasing Usage of Complex Biologics ... ... will rise from USD 20 Billion in 2015 to around USD ... Technologies - Innovation Driven by Rapidly Expanding Injectables Market and Increasing ...
Breaking Medicine Technology:
(Date:4/26/2017)... ... April 26, 2017 , ... ... an agile ecosystem and domain expertise for sponsors and CROs to speed ... trial supply management (RTSM) software platform. Bioclinica AGILE RTSM provides ...
(Date:4/25/2017)... ... April 25, 2017 , ... Splashtop Inc. , ... . This new addition to the Mirroring360 product family combines device screen mirroring ... Mirroring360 Pro enables educators, business professionals and individuals to stream or mirror app ...
(Date:4/25/2017)... NY (PRWEB) , ... April 25, 2017 , ... A ... stress at work can also decrease overall productivity and performance in the workplace. The ... employees. , During the last few weeks of April, Clearview Resolution Services will be ...
(Date:4/25/2017)... ... ... The doctors at Wall Centre Dental are now expanding their practice by accepting ... receive dental care. The doctors offer three treatment options to put victims of ... at their dental office in Vancouver. Wall Centre Dental is currently welcoming even patients ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... rely on contracted partners to help with process innovation in drug formulation and ... formulation experience along with state-of-the-art analytical equipment in support of their development and ...
Breaking Medicine News(10 mins):